Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.
  • ArrayPharmacy
  • call for care 214.379.2700

    Choice Cancer Care is here for you 9AM – 5PM Monday – Friday

    Inquiring after hours? Complete our contact form and we will be in touch as soon as possible.

    Call

  • Patientportal

    Access Your Portal To Health at Choice Cancer Care.

    Learn more about becoming a CCC Patient, including insurance information and patient rights, or login to access your personal portal for in-depth information about your health.

    LoginSign UpLearn More

  • Patientforms
  • get a second opinion

    Recent Diagnosis? Gain Confidence With A Second Opinion.

    Find out what to ask your doctor, what a second opinion could mean for you, and take the steps to get you on the right path to treat your cancer.

    Complete this form for a no obligation consultation:









  • certified

    Choice Cancer Care is proud to be recognized by the Quality Oncology Practice Initiative (QOPI®) for excellence in quality, and safety in the administration of cancer care.

    Learn More

Managing Oligometastatic Lung Cancer

Oligometastatic lung cancer is cancer that has spread from the primary location to one or a few other organs. In most cases, oligometastatic lung disease occurs in the brain. Synchronous oligomestatases can occur during the initial diagnosis, while metachronousoligometastases are seen within six months of diagnosis. The oligometastatic phenotype is typically a function of the current biology of cancer in the body.

In several clinical trials to manage oligometastatic lung cancer:

  • Oligometastatic non-small cell lung cancer patients who received locally ablative therapy after systematic therapy showed improvement in their progression-free survival and overall survival.
  • It was noted that most of the patients who benefited from this trial were those with 0 to 1 metastatic lesion.
  • In a screening study, patients with up to 5 metastatic foci in different types of cancers were given definitive treatment and standardized palliative therapy with stereotactic radiotherapy. Improvement in progression-free survival and overall survival was observed in this group as well. A randomized clinical trial is underway to confirm these results.

  • Another trial was conducted to assess the outcomes in patients with oligometastatic lung cancer when immunotherapy is added to locally ablative therapy. The patients were given pembrolizumab (Keytruda) for six months with excellent results.

These few trials and many others have confirmed that locally ablative therapy can be used as a treatment option for oligometastatic lung disease. As for immunotherapy, efforts are ongoing to help identify its biomarkers to help direct oncologists on the right patients who can receive the combination with definitive results.

Currently, randomized trials are being carried out to evaluate the efficacy of locally ablative therapy in treating oligometastatic lung cancer. Also, the role of immunotherapy has to be confirmed in such a setting to help improve outcomes for patients. Clinicians now have an essential job of identifying which patients can benefit from this therapy.

Cancer Screening Guidelines

Screening can help doctors discover and treat some types of cancer early. Usually, cancer treatment is more effective when the disease is detected in its early stages and there could be a better chance of curing the cancer. Some...

Learn More

Learn About Your Options

Your journey with cancer is influenced by several factors. These factors include your overall condition, the specific characteristics of your cancer, and whether the goal of treatment is to eradicate your cancer, stop your cancer from spreading to other areas...

Learn More